Clearmind says Japan publishes patent application on 3-MMC-based dyskinesia treatment

CMND•2026-10-08

Clearmind Medicine said a Japanese patent application covers 3-MMC-based methods and compositions to prevent or treat dyskinesia, including combinations with palmitoylethanolamide.

1. Patent application published

The application covers combining 3-MMC with palmitoylethanolamide to target an added anti-inflammatory or neuroprotective effect. The work is tied to Clearmind’s collaboration with NeuroThera Labs, which contributes palmitoylethanolamide technology to the therapeutic platform.

Clearmind says Japan publishes patent application on 3-MMC-based dyskinesia treatment

1. Patent application published

Related News

Tate & Lyle, BioHarvest hit milestone in next-generation sweetener programme

First Citizens, Huntington, BankUnited provide $173 million loan for Pivot Energy solar portfolio

Mission Produce targets mid-single-digit organic sales growth and 300 basis points of margin expansion over five years

Seven Hills Realty Trust declares quarterly dividend of $0.28 a share

NN, Inc. eliminates all of its preferred stock